| Name | Title | Contact Details |
|---|
A Global Development Expedition FOR women, not ABOUT women. Signature Leaders is designed to augment, rather than replace, existing corporate executive leadership development. These are programs for women with the highest potential, to fast-track them into next level leadership. These women are managing large P&Ls, leading transformations across the enterprise or sizeable functional teams, or in that critical "pivot" from managing to leading. We gather these elite leaders from around the world for introspective learning and external connections. Our executive faculty covers our framework of Who You Are, How You Show Up, and How You Relate to Others. Unlike typical seminars or conferences, participants will join the Signature community upon enrollment. This means the opportunities for learning and growth starts prior to, and continues beyond, the immersion session. Signature alumni move forward with an invaluable network of more than 2,300 peers and 250 executive faculty members and advisors who support them throughout their ongoing leadership journey. Why Signature as a name? Because every executive has a unique style and "signature" embedded in the way they lead. Our curriculum focuses on the essential capabilities needed for next level leadership in a way that encourages executives to broaden, not change their own distinct style – the leadership signature that makes them authentic.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Arkeyo offers self-service coin counting / cash dispensing kiosks to banks, casinos, grocery stores and other retail locations. Arkeyo is delivering high profile products and services designed to engage and efficiently monetize the growing need for a new self-service coin alternative in the USA and Europe. Clients can select from a full set of product lines, in their own language and their own currency. Arkeyo also picks up and processes coin bins and coin bags. Unlike legacy self-service coin offerings, Arkeyo gives retailers powerful tools to narrowcast their direct marketing, to identify and engage the right customer with the right offering at the right time, enhancing results and efficiency. Rules-based intelligence, routing and reporting tools offer retailers the opportunity to increase sales, lower customer service costs, shorten ‘float time and encourage repeat business. Through an affiliate program, users of the self-service coin machines can earn credit toward future purchases and exchange points with offline affiliate partners.